Do analysts prefer BFRG or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BFRG or ISPC more profitable?

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of -200.64% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -200.64% -162.83% iSpecimen -2,445.40% -491.18% -136.28%

Does the media prefer BFRG or ISPC?

In the previous week, Bullfrog AI had 1 more articles in the media than iSpecimen. MarketBeat recorded 4 mentions for Bullfrog AI and 3 mentions for iSpecimen. Bullfrog AI's average media sentiment score of 1.22 beat iSpecimen's score of 0.63 indicating that Bullfrog AI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bullfrog AI 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iSpecimen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VIVS or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, VIVS or ISPC?

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VivoSim Labs $130K 29.92 -$13.84M -$4.47 N/A iSpecimen $1.93M 1.77 -$10.49M -$56.44 N/A

Is VIVS or ISPC more profitable?

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -491.18% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets VivoSim Labs -11,016.07% -612.23% -177.02% iSpecimen -2,445.40% -491.18% -136.28%

Does the media refer more to VIVS or ISPC?

In the previous week, VivoSim Labs had 1 more articles in the media than iSpecimen. MarketBeat recorded 4 mentions for VivoSim Labs and 3 mentions for iSpecimen. iSpecimen's average media sentiment score of 0.63 beat VivoSim Labs' score of -0.02 indicating that iSpecimen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VivoSim Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iSpecimen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TBIO or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TBIO or ISPC more profitable?

Telesis Bio has a net margin of -336.59% compared to iSpecimen's net margin of -2,445.40%. Telesis Bio's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets Telesis Bio -336.59% N/A -61.89% iSpecimen -2,445.40% -491.18% -136.28%

Do analysts prefer ISPC or BFRGW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ISPC or BFRGW?

Bullfrog AI has lower revenue, but higher earnings than iSpecimen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iSpecimen $1.93M 1.77 -$10.49M -$56.44 N/A Bullfrog AI $116.67K N/A N/A N/A N/A

Is ISPC or BFRGW more profitable?

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -491.18% -136.28% Bullfrog AI N/A N/A N/A

Do analysts prefer ISPC or OABIW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ISPC or OABIW?

OmniAb has higher revenue and earnings than iSpecimen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iSpecimen $1.93M 1.77 -$10.49M -$56.44 N/A OmniAb $38.46M N/A N/A N/A N/A

Is ISPC or OABIW more profitable?

OmniAb has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. OmniAb's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -491.18% -136.28% OmniAb N/A N/A N/A

iSpecimen (ISPC) Competitors

$2.25 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.24 0.00 (-0.22%)

As of 08/14/2026 07:55 PM Eastern

Compare

ISPC vs. BFRG, VIVS, TBIO, BFRGW, and OABIW

Should you buy iSpecimen stock or one of its competitors? iSpecimen's main competitors and comparable companies include Bullfrog AI (BFRG), VivoSim Labs (VIVS), Telesis Bio (TBIO), Bullfrog AI (BFRGW), and OmniAb (OABIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does iSpecimen compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRG) and iSpecimen (NASDAQ:ISPC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of -200.64% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-200.64%	-162.83%
iSpecimen	-2,445.40%	-491.18%	-136.28%

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 14.7% of Bullfrog AI shares are held by insiders. Comparatively, 12.2% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bullfrog AI has a beta of -2.7, indicating that its stock price is 370% less volatile than the broader market. Comparatively, iSpecimen has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

Bullfrog AI has higher earnings, but lower revenue than iSpecimen. Bullfrog AI is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120K	87.79	-$6.50M	-$0.54	N/A
iSpecimen	$1.93M	1.77	-$10.49M	-$56.44	N/A

In the previous week, Bullfrog AI had 1 more articles in the media than iSpecimen. MarketBeat recorded 4 mentions for Bullfrog AI and 3 mentions for iSpecimen. Bullfrog AI's average media sentiment score of 1.22 beat iSpecimen's score of 0.63 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bullfrog AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iSpecimen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bullfrog AI beats iSpecimen on 9 of the 14 factors compared between the two stocks.

How does iSpecimen compare to VivoSim Labs?

VivoSim Labs (NASDAQ:VIVS) and iSpecimen (NASDAQ:ISPC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

In the previous week, VivoSim Labs had 1 more articles in the media than iSpecimen. MarketBeat recorded 4 mentions for VivoSim Labs and 3 mentions for iSpecimen. iSpecimen's average media sentiment score of 0.63 beat VivoSim Labs' score of -0.02 indicating that iSpecimen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iSpecimen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VivoSim Labs has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, iSpecimen has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by company insiders. Comparatively, 12.2% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$130K	29.92	-$13.84M	-$4.47	N/A
iSpecimen	$1.93M	1.77	-$10.49M	-$56.44	N/A

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -491.18% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-11,016.07%	-612.23%	-177.02%
iSpecimen	-2,445.40%	-491.18%	-136.28%

Summary

iSpecimen beats VivoSim Labs on 10 of the 13 factors compared between the two stocks.

How does iSpecimen compare to Telesis Bio?

Telesis Bio (NASDAQ:TBIO) and iSpecimen (NASDAQ:ISPC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

iSpecimen has lower revenue, but higher earnings than Telesis Bio. iSpecimen is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A
iSpecimen	$1.93M	1.77	-$10.49M	-$56.44	N/A

Telesis Bio has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, iSpecimen has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Telesis Bio has a net margin of -336.59% compared to iSpecimen's net margin of -2,445.40%. Telesis Bio's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telesis Bio	-336.59%	N/A	-61.89%
iSpecimen	-2,445.40%	-491.18%	-136.28%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, iSpecimen had 3 more articles in the media than Telesis Bio. MarketBeat recorded 3 mentions for iSpecimen and 0 mentions for Telesis Bio. iSpecimen's average media sentiment score of 0.63 beat Telesis Bio's score of 0.00 indicating that iSpecimen is being referred to more favorably in the news media.

Company	Overall Sentiment
Telesis Bio	Neutral
iSpecimen	Positive

37.6% of Telesis Bio shares are owned by institutional investors. Comparatively, 13.6% of iSpecimen shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by company insiders. Comparatively, 12.2% of iSpecimen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Telesis Bio beats iSpecimen on 9 of the 14 factors compared between the two stocks.

How does iSpecimen compare to Bullfrog AI?

iSpecimen (NASDAQ:ISPC) and Bullfrog AI (NASDAQ:BFRGW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, iSpecimen had 2 more articles in the media than Bullfrog AI. MarketBeat recorded 3 mentions for iSpecimen and 1 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.89 beat iSpecimen's score of 0.63 indicating that Bullfrog AI is being referred to more favorably in the news media.

Company	Overall Sentiment
iSpecimen	Positive
Bullfrog AI	Very Positive

13.6% of iSpecimen shares are held by institutional investors. 12.2% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bullfrog AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bullfrog AI has lower revenue, but higher earnings than iSpecimen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.77	-$10.49M	-$56.44	N/A
Bullfrog AI	$116.67K	N/A	N/A	N/A	N/A

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-491.18%	-136.28%
Bullfrog AI	N/A	N/A	N/A

Summary

iSpecimen beats Bullfrog AI on 5 of the 9 factors compared between the two stocks.

How does iSpecimen compare to OmniAb?

iSpecimen (NASDAQ:ISPC) and OmniAb (NASDAQ:OABIW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

13.6% of iSpecimen shares are held by institutional investors. 12.2% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OmniAb has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. OmniAb's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-491.18%	-136.28%
OmniAb	N/A	N/A	N/A

In the previous week, iSpecimen had 2 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for iSpecimen and 1 mentions for OmniAb. OmniAb's average media sentiment score of 1.87 beat iSpecimen's score of 0.63 indicating that OmniAb is being referred to more favorably in the news media.

Company	Overall Sentiment
iSpecimen	Positive
OmniAb	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

OmniAb has higher revenue and earnings than iSpecimen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.77	-$10.49M	-$56.44	N/A
OmniAb	$38.46M	N/A	N/A	N/A	N/A

Summary

OmniAb beats iSpecimen on 5 of the 9 factors compared between the two stocks.

Get iSpecimen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ISPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ISPC vs. The Competition

Export

Metric	iSpecimen	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.42M	$9.44B	$7.00B	$13.04B
Dividend Yield	N/A	1.46%	2.56%	10.42%
P/E Ratio	-0.04	60.31	271.56	25.35
Price / Sales	1.77	107.25	604.96	100.03
Price / Cash	N/A	26.11	28.87	38.43
Price / Book	0.15	5.06	11.22	6.52
Net Income	-$10.49M	$56.67B	$3.45B	$346.81M
7 Day Performance	0.45%	0.14%	1.02%	1.27%
1 Month Performance	7.14%	2.84%	2.35%	2.57%
1 Year Performance	-95.23%	17.42%	62.40%	20.83%

iSpecimen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ISPC iSpecimen	0.5443 of 5 stars	$2.25 flat	N/A	-95.2%	$3.42M	$1.93M	N/A	60	Earnings Report Gap Up
BFRG Bullfrog AI	1.5601 of 5 stars	$0.62 +7.4%	N/A	-54.5%	$10.66M	$116.67K	N/A	4	Positive News Earnings Report Gap Up
VIVS VivoSim Labs	0.146 of 5 stars	$0.37 +9.7%	N/A	-81.8%	$1.17M	$131K	N/A	20	Earnings Report Gap Down
TBIO Telesis Bio	N/A	$0.00 flat	N/A	-95.5%	$2K	$225.09M	N/A	200
BFRGW Bullfrog AI	N/A	$0.11 +2.7%	N/A	-71.9%	$0.00	$116.67K	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ISPC) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iSpecimen (ISPC) Competitors

ISPC vs. BFRG, VIVS, TBIO, BFRGW, and OABIW

How does iSpecimen compare to Bullfrog AI?

Summary

How does iSpecimen compare to VivoSim Labs?

Summary

How does iSpecimen compare to Telesis Bio?

Summary

How does iSpecimen compare to Bullfrog AI?

Summary

How does iSpecimen compare to OmniAb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ISPC vs. The Competition

iSpecimen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iSpecimen (ISPC) Competitors

ISPC vs. BFRG, VIVS, TBIO, BFRGW, and OABIW

How does iSpecimen compare to Bullfrog AI?

Is BFRG or ISPC more profitable?

Do institutionals and insiders hold more shares of BFRG or ISPC?

Which has more risk & volatility, BFRG or ISPC?

Which has better earnings & valuation, BFRG or ISPC?

Does the media prefer BFRG or ISPC?

Do analysts prefer BFRG or ISPC?

Summary

How does iSpecimen compare to VivoSim Labs?

Does the media refer more to VIVS or ISPC?

Do analysts prefer VIVS or ISPC?

Which has more volatility and risk, VIVS or ISPC?

Do insiders & institutionals believe in VIVS or ISPC?

Which has better valuation and earnings, VIVS or ISPC?

Is VIVS or ISPC more profitable?

Summary

How does iSpecimen compare to Telesis Bio?

Which has preferable valuation and earnings, TBIO or ISPC?

Which has more risk and volatility, TBIO or ISPC?

Is TBIO or ISPC more profitable?

Do analysts recommend TBIO or ISPC?

Does the media prefer TBIO or ISPC?

Do institutionals and insiders have more ownership in TBIO or ISPC?

Summary

How does iSpecimen compare to Bullfrog AI?

Does the media refer more to ISPC or BFRGW?

Do insiders & institutionals hold more shares of ISPC or BFRGW?

Do analysts prefer ISPC or BFRGW?

Which has stronger earnings and valuation, ISPC or BFRGW?

Is ISPC or BFRGW more profitable?

Summary

How does iSpecimen compare to OmniAb?

Do institutionals & insiders have more ownership in ISPC or OABIW?

Is ISPC or OABIW more profitable?

Does the media prefer ISPC or OABIW?

Do analysts prefer ISPC or OABIW?

Which has better earnings and valuation, ISPC or OABIW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ISPC vs. The Competition

iSpecimen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools